Generic-drug maker Sandoz Inc. is currently embroiled in a heated legal dispute with biopharmaceutical firm United Therapeutics Corp., with the contention centering around more than $160 million in damages. The ongoing litigation is a result of allegations that United Therapeutics effectively hindered the sale of Sandoz’s generic version of a popular hypertension medication.
The two companies have radically disparate estimates regarding the extent of damages faced by Sandoz due to the alleged market obstruction by United Therapeutics. The opening declarations of a bench trial that commenced Monday in a New Jersey federal court revealed this monetary chasm.
Further details on the litigation and the complex legal arguments involved are being unveiled as the court proceedings continue, bringing our understanding of this multifaceted dispute into sharper focus.